Intec Pharma Priced, Nasdaq: NTEC

Developing an improved delivery method of carbidopa/levodopa for Parkinson's disease.

Industry: Health Care

Latest Trade: $5.00 0.00 (0.0%)

First Day Return: +0.5%

Return from IPO: -16.7%

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on developing drugs based on our proprietary Accordion Pill platform technology, which we refer to as the Accordion Pill. Our Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention, or GR, and specific release mechanism. Our product pipeline currently includes two product candidates in clinical trial stages. Our leading product candidate, Accordion Pill Carbidopa/Levodopa, or AP-CDLD, is being developed for the indication of treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients. We have successfully completed a Phase II clinical trial for AP-CDLD for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients and have agreed with the FDA on the remaining clinical development program for AP-CDLD for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, including the main principles of the single required pivotal Phase III clinical trial in advanced Parkinson’s disease patients. We are preparing to commence a Phase III clinical trial for AP-CDLD for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients and currently anticipate that such trial will begin in the second half of 2015, assuming the successful completion of this offering. Our second product candidate, Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. We have successfully completed a Phase II clinical trial for AP–ZP for the treatment of insomnia under an IND application that we submitted to the FDA on August 4, 2009 for AP–ZP as a treatment for the induction and maintenance of sleep in patients suffering from insomnia.
more less
IPO News for Intec Pharma
more
IPO Data
IPO File Date 06/09/2015
Offer Price $6.00
Price Range $6.00 - $6.00
Offer Shares (mm) 5.0
Deal Size ($mm) $30
IPO Data
IPO Date 08/04/2015
Offer Price $6.00
Price Range $6.00 - $6.00
Offer Shares (mm) 5.0
Deal Size ($mm) $30
Underwriters
more
Company Data
Headquarters Jerusalem, Israel
Founded 2000
Employees 44
Website www.intecpharma.com